Concentra (NYSE: CON) Stock Analysis: Analyst Ratings and Expansion Drive Growth

• Analyst consensus: Concentra (NYSE: CON) has received Overweight/Buy ratings from Stephens, Wells Fargo (NYSE: WFC), JPMorgan Chase (NYSE: JPM), and Zacks.
• Strategic expansion: Concentra is actively growing its network of occupational health medical centers, notably expanding its presence in the Washington, D.C., area.
• Stock performance: The stock is currently trading at $38.18, positioned within its 52-week range of $18.55 to $39.60.

Concentra (NYSE: CON) operates occupational health medical centers that serve employers and workers. On October 19, 2026, Stephens initiates coverage with an Overweight rating, indicating that it expects the stock to perform better than its broader market benchmark. Concentra trades at $38.18 at the time.

Concentra is expanding in the Washington, D.C., area. As highlighted by Business Wire, a new Arlington, Virginia, center near Reagan Airport brings its regional network to more than 15 centers and gives Northern Virginia employers and employees another place to access occupational health services.

Other analysts also rate Concentra Overweight. Wells Fargo (NYSE: WFC) raises its price target from $28.00 to $40.00, while JPMorgan Chase (NYSE: JPM) raises its target from $34.00 to $43.00. A price target is an analyst’s estimate of where a stock could trade; it is not a guarantee.

As highlighted by Zacks, Concentra has a #2 (Buy) rank, compared with Medpace Holdings (NASDAQ: MEDP)’s #3 (Hold). That points to a stronger trend in analysts’ earnings-estimate changes for Concentra, but the comparison does not provide valuation figures or establish which stock is cheaper. Concentra’s $38.18 share price is within its past-year range of $18.55 to $39.60.